<DOC>
	<DOCNO>NCT03030222</DOCNO>
	<brief_summary>The primary purpose trial evaluate impact empagliflozin , compare placebo , hemodynamic parameter ( pulmonary artery diastolic pressure ) patient type 2 diabetes heart failure ( reduce preserve ejection fraction , ischemic non-ischemic etiology ) already CardioMEMs device implant non-study related clinical reason .</brief_summary>
	<brief_title>Empagliflozin Impact Hemodynamics Patients With Diabetes Heart Failure</brief_title>
	<detailed_description>A 12-week randomized , double-blind , placebo-controlled trial explore effect once-daily empagliflozin 10mg hemodynamic parameter ( pulmonary artery pressure ) patient type 2 diabetes mellitus heart failure ( reduce preserve ejection fraction , ischemic non-ischemic etiology ) already CardioMEMs device implant non-study related clinical reason .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>1 . Age &gt; 18 &lt; 120 screen visit 2 . Documented type 2 diabetes , treat least one glucoselowering medication ( oral , noninsulin injectables , insulin ) stable dose ( ) 12 week prior screen visit change screen randomization visit . Changes slide scale insulin dose consider disqualify change insulin dose . Changes total daily dose insulin ≤10 % baseline total daily dose consider disqualify change insulin dose . 3 . Hemoglobin A1c ≥6.5 % ≤11 % screen visit 4 . Established diagnosis heart failure ( least 16 week prior screen visit ) either preserve ( LVEF &gt; 40 % ) reduce systolic function ( LVEF≤40 % ) , due either ischemic nonischemic etiology , document imaging modality ( echocardiography , nuclear imaging , LV angiography , magnetic resonance imaging ) within past 24 month . 5 . No major change diuretic management 1 week prior screen visit screen randomization visit ( major change define double diuretic dose addition another diuretic medication ) 6 . NYHA class II , III IV heart failure symptom screen randomization visit 7 . Presence previously ( ≥ 4 week prior screen visit ) implant CardioMEMs pulmonary artery pressure monitor clinical indication unrelated study . 8 . PA diastolic pressure ≥ 12 mmHg time screen visit ( last measurement available prior screen visit ) . 9 . Ability provide inform consent prior initiate screen visit procedure 1 . Decompensated heart failure ( hospitalization heart failure within 4 week prior screen ) screen randomization 2 . History type 1 diabetes 3 . Hemoglobin A1c &gt; 11 % &lt; 6.5 % screen visit 4 . Major change diuretic management 1 week prior screen visit screen randomization visit . ( major change define double diuretic dose addition another diuretic medication ) 5 . Significant variability baseline PA diastolic pressure screen period . Defined change great +/ 6 mmHg average PA diastolic pressure week 1 screening phase average PA diastolic pressure week 2 screening phase patient average baseline PA diastolic pressure week 1 screening phase &lt; 30 mmHg . If average baseline PA diastolic pressure week 1 screening phase ≥30 mmHg , ≥20 % relative change average PA diastolic pressure week 1 week 2 screening phase use define significant variability . 6 . Initiation hydralazine , longacting nitrate , beta blocker , ACEI/ARBs Valsartan/sacubitril prior 4 week prior screen 7 . Estimated glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73 m2 screen visit 8 . Admission acute coronary syndrome ( STelevation MI , nonSTelevation MI , unstable angina ) , percutaneous coronary intervention , cardiac surgery within 60 day prior screen visit . 9 . Implantation cardiac resynchronization therapy ( CRT ) device within previous 90 day . 10 . Implantation CardioMEMs device within past 4 week . 11 . Planned cardiovascular revascularization ( percutaneous intervention surgical ) major cardiac surgery ( coronary artery bypass grafting , valve replacement , ventricular assist device , cardiac transplantation , surgery require thoracotomy ) , plan implantation CRT device within 90 day screen visit . 12 . Participation interventional clinical trial ( investigational drug device ) observational registry within 12 week prior screen visit . 13 . History hypersensitivity empagliflozin 14 . For woman childbearing potential : Current planned pregnancy currently lactate 15 . Life expectancy &lt; 1 year screen visit 16 . Patients volume deplete base upon physical examination time screen randomization visit 17 . PA diastolic pressure &lt; 12 mmHg time screen visit ( average last four measurement available prior screen visit ) . 18 . Patients currently treat SGLT2 inhibitor ( dapagliflozin , canagliflozin , empagliflozin ) receive treatment SGLT2 inhibitor within 12 week prior screen visit . 19 . Average supine systolic BP &lt; 90 mmHg screen randomization visit 20 . Past current document history bladder cancer 21 . Active Gross Hematuria 22 . Heart failure due restrictive cardiomyopathy , active myocarditis , constrictive pericarditis , severe stenotic valve disease , HOCM ( hypertrophic obstructive cardiomyopathy ) . 23 . History heart transplant . 24 . Patients heart transplant list 1a 1b status</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>119 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>diabetes</keyword>
	<keyword>heart failure</keyword>
	<keyword>empagliflozin</keyword>
	<keyword>SGLT-2 inhibitor</keyword>
</DOC>